Targeted Treatments for Cancer and Diabetes
Fundamentals
Profile:
Symbol: PMCB
HQ: Laguna Hills CA
Incorporated: 1996 as a neutraceutical firm. In 2013, restructured as a biopharma. In 2015 it changed its name from Nuvilex, Inc. to PharmaCyte Biotech.
Focus: Strong
PharmaCyte has licensed a medical technology called Cell in a Box, and is using it in early stage clinical trials to improve existing treatments for cancer and diabetes, by better controlling the place and time of the treatment’s release.
It is also developing new treatments for cancer and diabetes to deliver with this technology, some of these derived from cannabis (for cancer). The company currently reports little about these new treatments, but a lot about the Cell in a Box delivery technology.
Cell in a Box technology could eventually itself be a revenue-producing technology, with or without a new treatment. Cell in a Box potentially allows for more specific targeting of medical treatments such as chemotherapy to where the treatment is needed in the body, thus reducing the side effects in other parts of the body.
Size:
Market Cap: $54 mil
Enterprise Value: $53 mil
# of employees: 4
Markets: Strong
If they develop a marketable product, the initial market will be US, Europe.
Operations: Weak
Production: PharmaCyte does not yet produce a product
Distribution: No distribution yet (no sales or product yet)
Integration/Diversification:
Vertically integrated: No
Horizontally diversified: No, they currently are focused on one product
Financials: Weak (no revenue yet)
Management: Neutral
CEO: Kenneth L. Waggoner, salary $375k
CFO: Carlos A. Trujillo, salary, $275k
COO: Dr. Gerald W. Crabtree, salary $138k
Chief Science Officer: Dr. Gerald W. Crabtree, salary NA
Chief Medical Officer: Dr. Linda S. Sher M.D., salary NA
Branding: N/A
No
Valuation: Neutral (no revenue yet)
Current share price: $0.05
Price to Sales: NA (no sales) (Biopharma industry=7.5)
Price to Book: 8.3
EV / revenue: NA
Financings: N/A
Risks: High
The risks of investing in any cannabis company are currently high given the newness of the market. The risks of investing in this company are very high, since it does not yet have a product or any revenue or income.
Recommendation: Weak
In terms of investing, this company currently has a few positive points, but more than a few negative ones.
